SYNTHETIC PEPTIDES TO DEVELOP SIMIAN RETROVIRAL VACCINE

不溶性SRV-2包膜肽88-103特异性结合恒河猴抗- SRV-2中和抗体。 SRV-2肽97-103出现在表位上 其诱导SRV-2肽88-95的潜在T细胞活化特性， 两种病毒共有的SRV-1和SRV-2包膜肽。 SRV-1和SRV-2 肽-KLH缀合物将用于诱导恒河猴抗包膜肽 中和抗体 这些抗体将被测试它们的能力 在体外阻断病毒合胞体的形成，当恒河猴 使动物产生显著水平的SRV-1或SRV-2中和抗体 将用活的SRV-1或SRV-2病毒进行攻毒。 将使用SRV-1或SRV-2包膜肽来定义涉及的表位 在病毒特异性细胞毒性T淋巴细胞（CTL）和/或抗体依赖性 细胞毒性（ADCC）反应。 表位表征 与参与CTL和ADCC应答的表位相关， 探索可能增强病毒特异性CTL的免疫方案， ADCC回应。 具有增强的CTL和/或ADCC应答的恒河猴 可以允许病毒特异性CTL细胞系的发展，并确定 CTL和/或ADCC应答在针对SRV-1的保护中的作用，或 SRV-2病毒感染。 Raji细胞的NP 40提取物将用于分离病毒的受体。 约束力 由SRV-1肽150-157或gp 70制备的亲和吸附剂 将用于分离推定的受体。 受体分析 对于病毒结合将包括1）阻断合胞体形成的能力， Raji细胞中的病毒生长，2）放射性标记受体与 3）放射性标记肽的抑制 与SRV-1和/或SRV-2病毒相互作用。 分离的受体将是 用于制备多克隆和单克隆抗受体抗体。 我们的长期目标是确定SRV-1和SRV-2包膜肽， 用于诱导增强的中和抗体和/或CTL和ADCC 病毒特异性反应，可以提供疫苗，以保护非人类 逆转录病毒感染的灵长类动物 分离受体的可用性 抗受体抗体将用于研究病毒-宿主细胞 病毒相互作用，并确定可以被病毒感染的细胞范围。

The insoluble SRV-2 envelope peptide 88-103 specifically binds rhesus anti- SRV-2 neutralizing antibodies. SRV-2 peptide 97-103 appears to the epitope that induces potential T cell activating properties of SRV-2 peptide 88-95, SRV-1 and SRV-2 envelope peptides shared by both virus. SRV-1 and SRV-2 peptide-KLH conjugates will be used to induce rhesus anti-envelope peptide neutralizing antibodies. These antibodies will be tested for their ability to block syncytium formation of virus in vitro, and when the rhesus monkeys make significant levels of SRV-1 or SRV-2 neutralizing antibody the animals will be challenged with the live SRV-1 or SRV-2 virus. SRV-1 or SRV-2 envelope peptides will be used to define epitopes involved in virus specific cytotoxic T lymphocyte (CTL) and/or antibody dependent cellular cytotoxicity (ADCC) responses. Characterization of epitopes associated with epitopes involved in CTL and ADCC responses will permit us to explore immunization protocols that might enhance virus-specific CTL and ADCC responses. Rhesus monkeys having enhanced CTL and/or ADCC responses may permit the development of virus-specific CTL cell lines and determine the role of CTL and/or ADCC responses in the protection against SRV-1 or SRV-2 virus infection. A NP40 extract of Raji cells will be used to isolate the receptor for virus binding. Affinity adsorbents prepared from SRV-1 peptide 150-157 or gp 70 will be used to isolate the putative receptor. Analysis of the receptor for virus binding will include 1) ability to block syncytial formation of virus growth in Raji cells, 2) direct binding of radiolabeled receptor with SRV-1 and/or SRV-2 virus, and 3) inhibition of radiolabeled peptide interaction with SRV-1 and/or SRV-2 virus. The isolated receptor will be used to prepare polyclonal and monoclonal anti-receptor antibodies. Our long term goal is to define SRV-1 and SRV-2 envelope peptides that can be used to induce enhanced neutralizing antibodies and/or CTL and ADCC virus-specific responses that can provide a vaccine to protect nonhuman primates from retroviral infections. The availability of isolated receptor and anti-receptor antibodies will be used to study virus-host cell interactions and define the range of cells that can be infected by virus.